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Nuclear factor-jB (NF-jB) is an important regulator of cell
survival and has been shown to be constitutively active in
chronic lymphocytic leukemia (CLL) cells. Recently, a novel
NF-jB inhibitor, IMD-0354 (N-(3, 5-bis-triﬂuoromethyl-phenyl)-5-
chloro-2-hydroxy-benzamide), was shown to speciﬁcally inhibit
the phosphorylation of IjBa by IkB kinases, thus preventing
NF-jB release. In this study, we investigated if IMD-0354 can
inhibit NF-jB activation and induce apoptosis in CLL cells
in vitro. The rate of increase in apoptosis, drug sensitivity and
DNA-binding activity of NF-jB were studied using Annexin V
stainings, the ﬂuorometric microculture cytotoxicity assay and
electrophoretic mobility shift assay, respectively. Finally, the
impact of IMD-0354 treatment on the expression of a set of
apoptosis-related genes was investigated. The results clearly
show that IMD-0354 induced apoptosis (mean 26%, range
8–48%) in CLL cells, independent of immunoglobulin heavy
variable (IGHV) gene mutational status, and showed a dose-
dependent cytotoxic effect. IMD-0354 treatment also signiﬁ-
cantly lowered the DNA-binding activity of NF-jB in CLL cells.
In addition, we identiﬁed differences in expression levels of
pro- and antiapoptotic genes following IMD-0354 treatment. In
summary, our novel ﬁndings show that IMD-0354 can induce
apoptosis in CLL cells, and thus merits further investigation as
an anticancer agent in vivo.
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During the past decade, major advances in the treatment of
chronic lymphocytic leukemia (CLL) have been made, including
the emergence of promising agents, such as the nucleoside
analog ﬂudarabine and the monoclonal antibodies alemtuzu-
mab (anti-CD52) and rituximab (anti-CD20),
1,2 which have led
to higher response rates and longer periods of remission for CLL
patients. However, despite these therapeutic options, the
disease will progress for many patients, for instance, in patients
with poor-prognostic markers such as unmutated immuno-
globulin heavy variable (IGHV) genes or deletions of 11q/17p.
Hence, novel drugs for CLL treatment are needed, in which
agents interfering with the nuclear factor-kB (NF-kB) pathway
are one possible approach.
3
NF-kB is an important regulator that not only mediates
apoptotic signaling, but also plays critical roles in cell
proliferation, cell adhesion, inﬂammation, differentiation, angio-
genesis and tumor cell invasion.
4,5 Several studies suggest that
CLL cells display constitutive activation of NF-kB, which results
in a block of apoptosis for the malignant B cells.
3,6,7
NF-kB is a collective name for inducible dimeric transcription
factors composed of members of the Rel family of DNA-binding
proteins that recognize a common DNA sequence motif.
Human beings express ﬁve NF-kB/Rel proteins: p50, p52, p65
(RelA), c-Rel and RelB, in which homo/heterodimers containing
different combinations of these subunits are held in the
cytoplasm through interaction with speciﬁc inhibitors, the IkBs
(IkBa, IkBb and IkBg). The process leading to the activation of
NF-kB requires phosphorylation of IkB by IkB kinases (IKK),
resulting in the degradation of IkB by rapid ubiquitin-dependent
degradation. This allows the translocation of NF-kB from the
cytosol to the nucleus, in which the heterodimer binds to a
response element in the promoter region of speciﬁc target genes.
Previous studies have indicated that NF-kB inhibitors, such as
LC-1 and DHMEQ, can induce apoptosis in CLL cells, especially
when combined with ﬂudarabine.
8,9 These inhibitors have also
been able to accelerate apoptosis in CLL cells.
10 Deguelin is
another drug that has been shown to inhibit IkBa in CLL cells,
also leading to the induction of apoptosis.
11
Recently, the compound IMD-0354 (N-(3, 5-bis-triﬂuoro-
methyl-phenyl)-5-chloro-2-hydroxy-benzamide), which is a
novel inhibitor of IkB phosphorylation, was shown to induce
apoptosis in human mast cells with constitutively activated c-kit
receptors and was suggested to have therapeutic activity.
12
Speciﬁcally, IMD-0354 inhibits the IKK-induced phosphoryla-
tion of IkBa and hence protects it from undergoing degradation,
which in turn results in the inhibition of NF-kB activation. In this
study, we investigated the effect of IMD-0354 in CLL cells
in vitro by performing Annexin V stainings and a non-
clonogenic cytotoxicity assay. Furthermore, we investigated
the effect of IMD-0354 treatment on gene expression of different
pro- and antiapoptotic genes. Our data clearly show that
IMD-3054 can induce apoptosis of CLL cells directly by
inhibiting the NF-kB pathway and should be further investigated
as a new potential drug in CLL treatment.
Materials and methods
Patient samples
In total, tumor samples from 20 untreated CLL patients were
included in this study. CLL cells displayed the typical
immunophenotype and met the recently revised diagnostic
criteria.
13 Tumor material was obtained from peripheral blood
samples. The median age at diagnosis was 64 years (range,
44–85 years), with a male:female ratio of 4:1. Eleven cases
displayed IGHV unmutated genes and eight cases
IGHV mutated genes, whereas in one case the mutation status
was unknown. Informed consent was obtained according to the
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CLL cells were cultured in RPMI 1640 medium with 10% fetal
calf serum (Gibco, Paisley, UK) supplemented with the addition
of 4mM glutamine and 1  penicillin/streptomycin (Invitrogen,
Carlsbad, CA, USA) at a cell density of 1 10
6 cells per ml at
371Ci n5 %C O 2 atmosphere. CLL cell cultures were
maintained for 48h both with/without the addition of IMD-
0354 (Sigma Aldrich, St Louis, MO, USA) 1–10mM and the
survival factor thioredoxin (Trx)
14 (1mg/ml) (Sigma Aldrich).
Annexin V staining for detection of phosphatidyl serine exposed
on the plasma membrane was carried out using Annexin
V-ﬂuorescein isothiocyanate apoptosis detection kit (BD Bio-
sciences Pharmingen, San Diego, CA, USA) according to the
manufacturer’s instruction. In brief, cells were washed and
incubated for 15min in the dark with ITC-conjugated Annexin V
and propidium iodide provided with the kit and a minimum of
10000 events were collected on a Beckman Coulter FACSort
ﬂow cytometer. Apoptosis was calculated as the percentage of
Annexin V-positive cells corrected for the percentage occurring
owing to spontaneous apoptosis in control wells.
Fluorometric microculture cytotoxicity assay
The ﬂuorometric microculture cytotoxicity assay is a total cell
kill assay, based on the ability of cells with intact cell
membranes to convert non-ﬂuorescent diacetate to ﬂuorescent
ﬂuorescein.
15 Tumor cells from eight CLL samples were cultured
in 384-well microtiter plates that contained different concentra-
tions of IMD-0354 ranging from 0.01 to 100mM, and all samples
were run in duplicates. The plates were incubated at 371C and
5% CO2 for 72h and then analyzed using the automated
Optimized Robot for Chemical Analysis (Orca, Beckman
Coulter, Fullerton, CA, USA). Both the culture medium and
drug were aspirated from the plates, followed by two rounds of
cell washes in phosphate-buffered saline. Q2 buffer (containing
125mM NaCl and 25mM Hepes buffer, pH 7.4) was added
before the addition of 10mg/ml of ﬂuorescein diacetate (Sigma
Aldrich) to each well. The plates were incubated for 50min and
ﬂuorescence was measured in Fluostar Optima (BMG Techno-
logies, Offenburg, Germany) at 485nm/520nm. Cell survival
after exposure to the cytotoxic drug was presented as the
percentage of survival index, deﬁned as mean ﬂuorescence in
duplicate test wells in the percentage of control wells with blank
values subtracted. Thus, a low numerical value indicates a high
cytotoxic effect. A successful assay required a ratio of 45
between the signal in the control wells and the blank wells, a
coefﬁcient of variation of o30% in the control wells and a
tumor cell fraction exceeding 70% in the cell preparation.
Multiplex ligation-dependent probe ampliﬁcation
analysis
Cells from ﬁve CLL cases were cultured in the presence of the
tumor necrosis factor-a (25ng/ml), which was used to activate
the NF-kB pathway, for 24h with the subsequent the addition of
IMD-0354 (1mM) and collected after an additional 24h. RNA
was puriﬁed using the Ambion RNA extraction kit (Applied
Biosystems, Foster City, CA, USA) and concentrations measured
utilizing the NanoDrop instrument. Quality of RNA was
assessed using the Agilent 2100 Bioanalyzer (Agilent Techno-
logies, Santa Clara, CA, USA). Multiple ligation-dependent
probe ampliﬁcation (MLPA) RNA analysis was carried out using
SALSA RT-MLPA KIT R011-B1 Apoptosis mRNA (MRC-Holland,
Amsterdam, the Netherlands), for the analysis of 35 apoptosis-
related genes as per the manufacturer’s instruction. Brieﬂy,
100ng of total RNA was reverse transcribed using the RT primer
mix provided by the kit, which contains one RT primer for each
of the 35 different apoptosis-related genes and four control
genes in a single multiplex reaction. MLPA probes were
subsequently added and allowed to hybridize for 16h at
601C. Following hybridization, the probes were ligated with
ligase 65 and polymerase chain reaction ampliﬁed utilizing
FAM-labeled M13 primers. All polymerase chain reaction
products were analyzed on the Applied Biosystems 9700 DNA
sequencer (Applied Biosystems) using the GeneScan software.
Peak tables for each sample were exported from GeneScan to
Microsoft Excel, in which data normalization to the control gene
b-2-microglobulin was carried out. Normalized data sets were
grouped and analyzed for signiﬁcant differences to the Statistica
software (ver.7.1, Stat Soft, Tulsa, OK, USA) using the w
2-test
(signiﬁcance Po0.05). A heat map for visualization purposes
was generated in the open source multiexperiment viewer
software (http://www.tm4.org/mev), in which data were
adjusted to a 0–1 scale for color expression coding.
NF-kB activation by electrophoretic mobility shift assay
CLL cells (1 10
6 cells per ml) were treated both with/without
1mM of IMD-0354 for 24h. Cytoplasmic and nuclear extracts
were prepared using hypotonic buffer (20mm Hepes, pH 7.6,
20% (w/v) glycerol, 20mm NaCl, 10mm MgCl2, 0.2mm EDTA,
1% (w/v) Triton X-100, 1mm dithiothreitol, 1mm sodium
orthovanadate and 1% aprotinin) and hypertonic buffer (20mm
Hepes, pH 7.6, 20% (w/v) glycerol, 500mm NaCl, 1.5mm
MgCl2, 0.2mm EDTA, 1% (w/v) Triton X-100, 1mm dithio-
threitol, 1mm sodium orthovanadate and 1% aprotinin),
respectively. Brieﬂy, cells were washed twice with phosphate-
buffered saline, and lysed in hypotonic buffer, for 10min on ice.
Nuclei were spun down and incubated in hypertonic lysis buffer
for 20min on ice. Supernatants were removed and protein
concentrations were determined. The NF-kB-speciﬁc consensus
oligonucleotide (50-AGTTGAGGGTTTCCCAGGC-30; Promega,
Madison, WI, USA) was 50 end labeled with [g-
32P]adenosine
triphosphate using polynucleotide kinase (Gibco, Gaithersburg,
MD, USA). For the binding reactions, equal quantities of nuclear
extracts (1–4mg) were incubated with 10000 c.p.m. of end-
labeled NF-kB oligonucleotide and 1mg of poly dI–dC
(GE Health Care, Buckinghamshire, UK) in the binding buffer
(20mm Hepes, pH 7.6, 20% (w/v) glycerol, 100mm NaCl,
10mm MgCl2, 0.2mm EDTA, 1% (w/v) Triton X-100, 1mm
dithiothreitol). Free oligonucleotide and oligonucleotide-bound
proteins were separated by electrophoresis on a native
6% polyacrylamide gel. Gels were dried under vacuum on
Whatman paper and exposed to Kodak BioMax MS ﬁlm
(Sigma Aldrich) for 3–6h at  801C. The absence of binding in
the presence of excess unlabeled NF-kB-speciﬁc oligonucleo-
tide (competitor oligonucleotide) conﬁrmed NF-kB-binding
speciﬁcity.
Results
IMD-0354 induces apoptosis in CLL cells in vitro
To determine whether IMD-0354 is capable of inducing
apoptosis in CLL cells in vitro, cells from 20 CLL patients were
incubated in the presence and absence of IMD-0354. The
survival factor Trx was added in cells from 10 of these patients
(ﬁve IGHV mutated and ﬁve IGHV unmutated samples). The
percentage of early apoptotic and viable cells was evaluated
by Annexin V/IP ﬂow cytometry after 48h of incubation. The
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increase over spontaneous apoptosis in untreated controls
samples at that time point. Overall, the majority of CLL samples
investigated showed an increase in the percentage of apoptotic
cells following treatment with IMD-0354 only (mean 26%,
range 8–48%), whereas treatment with IMD-0354þTrx gave a
somewhat lower mean percentage of apoptosis (mean 20%,
range 10–30%) (Figures 1a and b). On the contrary, CLL cells
treated with Trx alone (n¼10) did not show any apoptosis. Out
of total 20 CLL samples with IMD-0354 treatment, the
percentage of average mean increase in apoptosis for all
unmutated samples was 30% and for all mutated samples 25%.
CLL cells in duplicate (from two patients) were also incubated
with increasing amounts of IMD-0354, with concentrations
ranging from 1 to 10mM. A dose-dependent increase in
the apoptotic response of CLL cells was observed after 24h of
IMD-0354 incubation (Figure 1c).
Dose-dependent inhibition of CLL cell survival in vitro
To measure the cytotoxicity of IMD-0354 and calculate the
percentage of surviving CLL cells, we performed ﬂuorometric
microculture cytotoxicity assay. Tumor cells from eight CLL
samples were cultured in 384-well microtiter plates with
different concentrations of IMD-0354. The percentage of cell
survival was calculated as outlined in the Materials and methods
section. As shown in Figure 2, all CLL patient samples showed a
dose-dependent decrease in the percentage of survival index,
with increasing concentrations of IMD-0354.
Inhibition of NF-kB activation in CLL cells
To determine the DNA-binding activity of NF-kB in both IMD-
0354-treated and -untreated CLL cells, for four CLL samples, we
performed electrophoretic mobility shift assay, using a small
consensus NF-kB binding site. As shown in Figure 3, the DNA-
binding activity of NF-kB is almost lost in the IMD-0354-treated
CLL cells (lanes 6–9), as compared with the untreated cells,
which displayed a high DNA-binding activity (lanes 2–5).
The cold competition experiment, which was performed using
100-fold excess of unlabeled oligonucleotide, showed a
complete loss of DNA-binding activity (lane 10). These results
indicate that the activity of NF-kB is signiﬁcantly lowered
following 24h of IMD-0354 treatment in all four CLL samples.
Induction of apoptotic-related gene expression in
CLL cells
The above results indicated that IMD-0354 signiﬁcantly induced
apoptosis by targeting NF-kB-inducing genes and hence
decreased the cell survival in CLL patient samples in vitro.T o
test for changes in the expression of apoptotic genes in both
IMD-0354-treated and -untreated CLL cells, the expression
changes of 35 different apoptosis-related genes was investigated
by applying the RT-MLPA kit in ﬁve CLL samples. Cells were ﬁrst
treated with tumor necrosis factor-a for 24h, with subsequent
addition of IMD-0354 for another 24h and thereafter total RNA
was extracted. Signiﬁcant differences (Po0.05) in gene expres-
sion were only observed for three genes (BIRC2, BIRC3 and
BBC3) (Figure 4). To conﬁrm gene expression levels observed
with MLPA, we selected four genes (BCL2, BCL2A1, BAX and
MCL2) and veriﬁed the results using quantitative real-time-
polymerase chain reaction (data not shown).
60
45
30
%
 
a
p
o
p
t
o
s
i
s
 
o
v
e
r
 
s
p
o
n
t
a
n
e
o
u
s
 
r
a
t
e
 
o
f
 
C
L
L
 
c
e
l
l
s
15
0
–15
IMD-0354 (n=20) Trx IMD-0354+trx
(n=10)
Mean
(n=10)
–30
104
104
CLL cells after 48 hours culture
103
103
102
102
Annexin V
control cells
40
35
30
25
20
15
10
1µM2 µM3 µM
IMD-0354 concentration
4µM5 µM1 0 µM
5
0
%
 
i
n
c
r
e
a
s
e
 
i
n
 
a
p
o
p
t
o
s
i
s
 
o
v
e
r
s
p
o
n
t
a
n
e
o
u
s
 
r
a
t
e
P
I
101
101 100
104
103
102
P
I
101
100
100 104 103 102
Annexin V
CLL cells+IMD-0354
101 100
c
b
a
Figure 1 IMD-0354 induces apoptosis in CLL cells in vitro.( a) The
percentage of increased apoptosis in CLL samples (n¼20) cultured
in vitro with 1mM IMD-0354 either alone (n¼10) or in the presence of
Trx (n¼10). (b) Representative ﬂow cytometry analysis of apoptosis in
CLL cells with and without IMD-0354 treatment after 48h of incubation.
(c) Dose response to IMD-0354 after incubation for 24h, as measured by
Annexin V, based on the average results after culturing two CLL
samples. All cultures were carried out in duplicate.
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Figure 2 Fluorometric microculture cytotoxicity assay of CLL cells
treated with IMD-0354. Survival index (SI) of CLL cells from eight CLL
patients with increasing concentrations of IMD-0354 after 72h of
incubation.
A novel NF-jB inhibitor in CLL
M Kanduri et al
3
Blood Cancer JournalDiscussion
Many studies have shown that constitutive activation of NF-kBi s
a hallmark for most types of human cancer including leukemia
and lymphoma.
16,17 Given the considerable contribution of
NF-kB to proliferation in many cancers, NF-kB could be one
of the important molecular targets of therapy and inhibition of
NF-kB may also have a therapeutic potential for the control
of tumor progression. In this study, we applied a novel drug,
IMD-0354, to inhibit NF-kB activation in CLL cells in vitro.
IMD-0354 has been shown to inhibit proliferation of neoplastic
cells and results in suppressed progression in human breast cancer
and mast cells.
12,18 It has also been shown in mice models that
IMD-0354 treatment can signiﬁcantly reduce colitis-associated
tumorogenesis.
19 However, to our knowledge, the effect of IMD-
0354 in CLL has previously not been investigated.
The phenotype of CLL cells is characterized by defects in both
programmed cell death and control of proliferation.
20 When
applying IMD-0354, a clear increase in apoptosis was observed
in the majority of CLL samples investigated (Figure 1a). As it is
well known that CLL cells will rapidly undergo spontaneous
apoptosis when cultured in vitro,
21 we also added a survival
factor (Trx)
14 when performing the IMD-0354 experiments, to
prevent or reduce apoptosis in CLL cells. Despite this, a similar
increase in the level of apoptosis was observed for treatments,
including IMD-0354 alone or IMD-0354 along with Trx, which
indicates that IMD-0354 indeed can induce apoptosis in CLL
cells in vitro (Figure 1). Importantly, IMD-0354 also induced
apoptosis at similar levels in both IGHV mutated and
unmutated subgroups of CLL cases, indicating that both these
prognostic subgroups respond similarly to the effect of IMD-0354.
In addition, we measured the cytotoxic effect of IMD-0354 on the
CLL cells using ﬂuorometric microculture cytotoxicity assay, and
all cases showed an increase in cytotoxicity in a dose-dependent
manner (Figure 2).
IMD-0354 is thought to induce apoptosis by inhibiting the
degradation of IkB and thereby protecting it against phospho-
rylation, which in turn inhibits NF-kB activation. To show the
direct inhibition of NF-kB activity, we performed electrophore-
tic mobility shift assay to determine and compare the
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consensus oligonucleotide using nuclear extracts from four CLL
samples with and without IMD-0354 treatment. Lane 1, probe alone;
lanes 2–5, CLL patient samples without IMD-0354 treatment; and
lanes 6–9, CLL samples treated with 1mM IMD-0354. In lane 10, a
100-fold excess of unlabeled probe was added to the reaction,
containing the same lysates from CLL patient 1 sample mix (lane 2)
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Figure 4 Multiplex ligation-dependent probe ampliﬁcation analysis
before and after IMD-0354 treatment. (a) Apoptotic-related MLPA
expression data for ﬁve CLL samples without (column 1–5) or with
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treatment in CLL cell nuclear extracts. Signiﬁcant reduction in
DNA-binding activity of NF-kB was observed after IMD-0354
treatment (Figure 3), hence indicating that IMD-0354 indeed
induced apoptosis in CLL cells by direct targeting of NF-kB.
Reduction of NF-kB may result in signiﬁcant changes in
expression patterns of apoptotic-related genes, which may
include both anti- and proapoptotic BCL2 family members.
The BCL2 proteins are well-characterized regulators of apopto-
sis and can both promote survival (antiapoptotic) and
induce cell death (proapoptotic), and hence play an important
role in oncogenesis.
22,23 We explored possible changes in
gene expression of several apoptosis-related genes before and
after the IMD-0354 treatment in CLL cells using the MLPA
technique. After the IMD-0354 treatment, signiﬁcant
reduction of gene expression was observed for the antiapoptotic
BIRC3 and BIRC2 genes. These two genes are IAP family
members, which are known to be highly expressed in cancer
cells compared with normal cells.
24 BBC3, also known as
PUMA, was the only proapoptotic gene that showed signiﬁcant
increase in the expression after IMD-0354 treatment. PUMA is a
proapoptotic member of the BCL2 family, which mediates
p53-dependent and -independent apoptosis.
25 Hence, these
results suggest that IMD-0354 induces apoptosis in CLL cells by
decreasing and increasing anti- and proapoptotic genes,
respectively.
Taken together, we conclude that IMD-0354 speciﬁcally
targets the NF-kB pathway, and signiﬁcantly induces apoptosis
in CLL cells in vitro. This effect was retained when adding
the survival factor Trx and the drug was equally effective
in subgroups deﬁned by the IGHV mutational status. We
encourage further investigations of this drug as it may represent
a novel potential drug in CLL treatment.
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